Pharmacologic Management of Insomnia: Past, Present, and Future

Psychiatric Clinics of North America

Volumn 29, Issue 4, 2006, Pages 871-893

  Curry, Denise Troy ^a   Eisenstein, Rhody D ^a   Walsh, James K ^a  

^a ST LUKE S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; DIPHENHYDRAMINE; DOXEPIN; DOXYLAMINE; ESTAZOLAM; ESZOPICLONE; FLUOXETINE; FLURAZEPAM; FLUVOXAMINE; HORMONE RECEPTOR STIMULATING AGENT; HYDROXYZINE; HYPNOTIC SEDATIVE AGENT; MELATONIN; MELATONIN RECEPTOR AGONIST; MIRTAZAPINE; OLANZAPINE; QUAZEPAM; QUETIAPINE; RAMELTEON; TEMAZEPAM; TRAZODONE; TRIAZOLAM; TRIMIPRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALERIAN; ZALEPLON; ZOLPIDEM; INDENE DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; AMNESIA; AROUSAL; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EVIDENCE BASED MEDICINE; FALLING; HAMILTON SCALE; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; INJURY; INSOMNIA; LETHAL DOSE; LEUKOPENIA; LIVER DISEASE; LIVER TOXICITY; LONG TERM CARE; MEMORY DISORDER; MOOD DISORDER; MOTOR DYSFUNCTION; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRESCRIPTION; PRIAPISM; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; REBOUND; RESPIRATION DEPRESSION; REVIEW; RISK FACTOR; SEDATION; SELF MEDICATION; SHORT COURSE THERAPY; SIDE EFFECT; SLEEP; SLOW WAVE SLEEP; SOMNOLENCE; TESTOSTERONE BLOOD LEVEL; THROMBOCYTOPENIA; TREATMENT DURATION; WEIGHT GAIN; XEROSTOMIA; DRUG THERAPY; FORECASTING; METHODOLOGY; PHYTOTHERAPY;

DRUG THERAPY; FORECASTING; HUMANS; HYPNOTICS AND SEDATIVES; INDENES; PHYTOTHERAPY; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 33751014541     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2006.09.006     Document Type: Review

References (98)

1. Institute of Medicine. Sleeping pills, insomnia, and medical practice (1979), National Academy of Sciences, Washington, DC
2. Walsh J.K., and Schweitzer P.K. Ten year trends in the pharmacologic treatment of insomnia. Sleep 22 (1999) 371-375
3. Trans-NIH Sleep Research Coordinating Committee. 2003 National Sleep Disorders Research Plan. Bethesda, MD: National Institutes of Health, U.S. Dept. of Health and Human Services; 2003. NIH publication 03-5209.
4. Roehrs T., Hollebeek E., Drake C., et al. Substance use for insomnia in Metropolitan Detroit. J Psychosom Res 53 (2002) 571-576
5. Schweitzer P.K., Muehlbach M.J., and Walsh J.K. Sleepiness and performance during three-day administration of cetirizine or diphenhydramine. J Allergy Clin Immunol 94 (1994) 716-724
6. Richardson G.S., Roehrs T.A., Rosenthal L., et al. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 22 (2002) 511-515
7. National Institutes of Health State of the Science Conference. Manifestations and Management of Chronic Insomnia in Adults. Sleep 28 (2005) 1049-1057
8. Nutt D. GABA-A receptors: subtypes, regional distribution, and function. J Clin Sleep Med 2 (2006) S7-S11
9. Holbrook A.M., Crowther R., Lotter A., et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. [review]. CMAJ 162 (2000) 225-233
10. Nowell P.D., Mazumdar S., Buysse D.J., et al. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. [review]. JAMA 278 (1997) 2170-2177
11. Walsh J.K., Pollack C.P., Scharf M.B., et al. Lack of residual sedation following middle of the night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol 23 (2000) 17-21
12. Scharf M.B., Roth T., Vogel G.W., et al. A multi-center, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 55 (1994) 192-199
13. Walsh J.K., Vogel G.W., Scharf M., et al. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 1 (2000) 41-49
14. Oswald I., French C., Adam K., et al. Benzodiazepine hypnotics remain effective for 24 weeks. Br Med J (Clin Res Ed) 284 (1982) 860-863
15. Krystal A.D., Walsh J.K., Laska E., et al. Sustained efficacy of eszopiclone over six months of nightly treatment: results of a randomized, placebo-controlled study in adults with chronic insomnia. Sleep 26 (2003) 793-799
16. Roth T., Walsh J.K., Krystal A., et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 6 (2005) 487-495
17. Walsh J.K., Roth T., Randazzo A., et al. Eight weeks of non-nightly administration of zolpidem in the treatment of patients with primary insomnia. Sleep 23 (2000) 1087-1096
18. Perlis M.L., McCall W.V., Krystal A.D., et al. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry 65 (2004) 1128-1137
19. Ohayon M.M., Caulet M., Arbus L., et al. Are prescribed medications effective in the treatment of insomnia complaints?. J Psychosom Res 47 (1999) 359-368
20. Balter MB, Uhlenhuth EH. The beneficial and adverse effects of hypnotics. J Clin Psychiatry 1991;52(Suppl):16-23.
21. Walsh J.K., Muehlbach M.J., Lauter S.A., et al. Effects of triazolam on sleep, daytime sleepiness, and morning stiffness in patients with rheumatoid arthritis. J Rheumatol 23 (1996) 245-252
22. Doghramji K., Browman C.P., Gaddy J.R., et al. Triazolam diminishes daytime sleepiness and sleep fragmentation in patients with periodic limb movements in sleep. J Clin Psychopharmacol 11 (1991) 284-290
23. Roehrs T., Zorick F., Wittig R., et al. Efficacy of a reduced triazolam dose in elderly insomniacs. Neurobiol Aging 6 (1985) 293-296
24. Fava M., McCall W.V., Krystal A., et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 59 (2006) 1052-1060
25. Curran H.V., Collins R., Fletcher S., et al. Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood, and quality of life. Psychol Med 33 (2003) 1223-1237
26. Pat McAndrews M., Weiss R.T., Sandor P., et al. Cognitive effects of long-term benzodiazepine use in older adults. Hum Psychopharmacol 18 (2003) 51-57
27. Kelly K.D., Pickett W., Yiannakoulias N., et al. Medication use and falls in community-dwelling older persons. Age Ageing 32 (2003) 503-509
28. Brassington G.S., King A.C., and Bliwise D.L. Sleep problems as a risk factor for falls in a sample of community-dwelling adults aged 64-99 years. J Am Geriatr Soc 48 (2000) 1234-1240
29. Avidan A.Y., Fries B.E., James M.L., et al. Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc 53 (2005) 955-962
30. Mellinger G.D., Balter M.B., and Uhlenhuth E.H. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry 42 (1985) 225-232
31. Roehrs T., Hollebeek E., Drake C., et al. Substance use for insomnia in Metropolitan Detroit. J Psychosom Res 53 (2002) 571-576
32. Roehrs T., Pedrosi B., Rosenthal L., et al. Hypnotic self administration and dose escalation. Psychopharmacology (Berl) 127 (1996) 150-154
33. Roehrs T., Merlotti L., Zorick F., et al. Rebound insomnia in normals and patients with insomnia after abrupt and tapered discontinuation. Psychopharmacology (Berl) 108 (1992) 67-71
34. Kato K., Hirai K., Nishiyama K., et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 48 (2005) 301-310
35. Erman M., Seiden D., and Zammit G. Phase II study of the selective ML-1 receptor agonist TAK-375 in subjects with primary chronic insomnia. [abstract]. Sleep 26 Suppl (2003) A298
36. Zammit G., Roth T., Erman M., et al. Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia. Sleep 28 (2005) A229 [abstract]
37. Seiden D., Zee P., Weigand S., et al. Double-blind, placebo-controlled outpatient clinical trial of ramelteon for the treatment of chronic insomnia in an elderly population. [abstract]. Sleep 28 (2005) A228
38. Roth T., Stubbs C., and Walsh J.K. Ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 28 (2005) 303-307
39. Richardson G, Zammit G, Rodriguez L, et al. Evaluation of circadian phase-shifting effects of ramelteon in healthy subjects. Presented at the International Congress of Applied Chronobiology & Chronomedicine. June 1-5, 2005, Antalya, Turkey.
40. Griffiths R., Suess P., and Johnson M. Ramelteon and triazolam in humans: behavioral effects and abuse potential. Sleep 28 (2005) A44
41. Brogden R.N., Heel R.C., Speight T.M., et al. Trazodone: a review of its pharmacologic properties and therapeutic use in depression and anxiety. Drugs 21 (1981) 401-429
42. Jenck F., Moreau J.L., Mutel V., et al. Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol 231 (1993) 223-229
43. Frazer A. Pharmacology of antidepressants. J Clin Psychopharmacol 17 Suppl 1 (1997) 2S-18S
44. Preskorn S.H. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry 54 Suppl (1993) 14-34
45. Richelson E. The pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiatry 55 Suppl A (1994) 34-39
46. De Boer T. The pharmacological profile of mirtazapine. J Clin Psychiatry 57 Suppl 4 (1996) 19-25
47. Radhakishun F.S., van den Bos J., van der Heijden B.C., et al. Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J Clin Psychopharmacol 20 (2000) 531-537
48. Walsh J.K., Erman M., Erwin C.W., et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol 13 (1998) 191-198
49. Montgomery I., Oswald I., Morgan K., et al. Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol 16 (1983) 139-144
50. Riemann D., Voderholzer U., Cohrs S., et al. Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Pharmacopsychiatry 35 (2002) 165-174
51. Hohagen F., Montero R.F., Weiss E., et al. Treatment of primary insomnia with trimipramine: an alternative to benzodiazepine hypnotics?. Eur Arch Psychiatry Clin Neurosci 244 (1994) 65-72
52. Hajak G., Rodenbeck A., Voderholzer U., et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry 62 (2001) 453-463
53. Gillin J.C., Wyatt R.J., Fram D., et al. The relationship between changes in REM sleep and clinical improvement in depressed patients treated with amitriptyline. Psychopharmacol (Berl) 59 (1978) 267-272
54. Hartmann E., and Cravens J. The effects of long-term administration of psychotropic drugs on human sleep: III. The effects of amitriptyline. Psychopharmacologia 33 (1973) 185-202
55. Winokur A., Sateia M.J., Hayes J.B., et al. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biol Psychiatry 48 (2000) 75-78
56. Mir S., and Taylor D. The adverse effects of antidepressants. [mood disorders]. Curr Opin Psych 10 (1997) 88-94
57. Mendelson W.B. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 66 (2005) 469-476
58. Kudo Y., and Kurihara M. Clinical evaluation of diphenhydramine hydrochloride for the treatment of insomnia in psychiatric patients: a double-blind study. J Clin Pharmacol 30 (1990) 1041-1048
59. Rickels K., Morris R.J., Newman H., et al. Diphenhydramine in insomniac family practice patients: a double-blind study. J Clin Pharmacol 23 (1983) 234-242
60. Juri C., Chana P., Tapia J., et al. Quetiapine for Insomnia in Parkinson Disease: results from an open-label trial. Clin Neuropharmacol 28 (2005) 185-187
61. Estivill E., de la Fuente V., Segarra F., et al. The use of olanzapine in sleep disorders. An open trial with nine patients. Rev Neurol 38 (2004) 829-831
62. Dubocovich M.L., Masana M.I., and Benloucif S. Molecular pharmacology and function of melatonin receptor subtypes. Adv Exp Med Biol 460 (1999) 181-190
63. Buysse D.J., Schweitzer P.K., and Moul D.E. Clinical psychopharmacology of other drugs used as hypnotics. In: Kryger M.H., Roth T., and Dement W.C. (Eds). Principles and practice of sleep medicine. 4th ed. (2005), Elsevier Saunders, Philadelphia 452-467
64. Hughes R.J., and Badia P. Sleep-promoting and hypothermic effects of daytime melatonin administration in humans. Sleep 20 (1997) 124-131
65. James S.P., Mendelson W.B., Sack D.A., et al. The effect of melatonin on normal sleep. Neuropsychopharmacology 1 (1987) 41-44
66. Dollins A.B., Zhadnova I.V., Wurtman R.J., et al. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci U S A 91 (1994) 1824-1828
67. James S.P., Sack D.A., Rosenthal N.E., et al. Melatonin administration in insomnia. Neuropsychopharmacology 3 (1990) 19-23
68. Fischer S., Smolnik R., Herms M., et al. Melatonin acutely improves the neuroendocrine architecture of sleep in blind individuals. J Clin Endocrinol Metab 88 (2003) 5315-5320
69. Lusardi P., Preti P., Savino S., et al. Effect of bedtime melatonin ingestion on blood pressure of normotensive subjects. Blood Press Monit 2 (1997) 99-103
70. Lusardi P., Piazza E., and Fogari R. Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study. Br J Clin Pharmacol 49 (2000) 423-427
71. Naylor S., Johnson K.L., Williamson B.L., et al. Structural characterization of contaminants in commercial preparations of melatonin by on-line HPLC-electrospray ionization-tandem mass spectrometry. Adv Exp Med Biol 467 (1999) 769-777
72. Rogers N.L., Kennaway D.J., and Dawson D. Neurobehavioral performance effects of daytime melatonin and temazepam administration. J Sleep Res 12 (2003) 207-212
73. US Food and Drug Administration Center for Food Safety and Applied Nutrition, Office of Nutritional Products, Labeling, and Dietary Supplements. Information paper on L-tryptophan and 5-hydroxy-L-tryptophan. February 2001.
74. Michelson D., Page S.W., Casey R., et al. An eosinophilia-myalgia syndrome related disorder associated with exposure to l-5-hydroxytryptophan. J Rheumatol 21 (1994) 2261-2265
75. Varga A., Peltonen N., Uitto J., et al. Development of diffuse fasciitis with eosinophilia during l-tryptophan treatment: demonstration of elevated type I collagen gene expression in affected tissues. A clinicopathologic study of four patients. Ann Intern Med 112 (1990) 344-351
76. Smith M.J., and Garrett R.H. A heretofore undisclosed crux of eosinophilia-myalgia syndrome: compromised histamine degradation. Inflamm Res 54 (2005) 435-450
77. Vissiennon Z., Sichardt K., Koetter U., et al. Valerian extract ze 911 inhibits postsynaptic potential by activation of adenosine A1 receptors in rat cortical neurons. Planta Med (Stuttgart) 72 (2006) 770
78. Balderer G., and Borbely A.A. Effect of valerian on human sleep. Psychopharmacology (Berl) 87 (1985) 406-409
79. Donath F., Quispe S., Diefenbach K., et al. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry 33 (2000) 47-53
80. Schulz H., Stolz C., and Muller J. The effect of valerian extract on sleep polygraphy in poor sleepers: a pilot study. Pharmacopsychiatry 27 (1994) 147-151
81. Lefebrve T., Foster B.C., Drouin C.E., et al. In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J Pharm Pharm Sci 7 (2004) 265-273
82. Donovan JL, DeVane CL, Chavin KD, et al. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos 2004;32:1333-6.
83. Garges H.P., Varia I., and Doriaswamy P.M. Cardiac complications and delirium associated with valerian root withdrawal. [letter]. JAMA 280 (1998) 1566-1567
84. Plushner S.L. Valerian: Valeriana officinalis. Am J Health Syst Pharm 54 (2000) 328, 333, 335
85. O'Neil C.K., Avila J.R., and Fetrow C.W. Herbal medicines: getting beyond the hype. Nursing (Brux) 29 (1999) 58-61
86. National Institute of Mental Health. Consensus conference report: drugs and insomnia-the use of medication to promote sleep. JAMA 251 (1984) 2410-2414
87. Mendelson W.B., Roth T., Cassella J., et al. The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit (NCDEU) meeting symposium. Sleep Med Rev 8 (2004) 7-17
88. McCall W.V. Pharmacologic treatment of insomnia. In: Lee-Chiong Jr. T.L., Sateia M.J., and Carskadon M.A. (Eds). Sleep medicine (2002), Hanley & Belfus, Philadelphia 169-176
89. Roehrs T., and Roth T. Hypnotics: an update. Curr Neurol Neurosci Rep 3 (2003) 181-184
90. Ohayon M.M. Prevalence of DSM-IV diagnostic criteria of insomnia: distinguishing insomnia related to mental disorders from sleep disorders. J Psychiat Res 31 (1997) 333-346
91. Buysse D.J., Reynolds III C.F., Kupfer D.J., et al. Clinical diagnoses n 216 insomnia patients using the international classification of sleep disorders (ICSD), DSM-IV and ICD-10 categories: a report from the APA/NIMH DSM-IV field trial. Sleep 17 (1994) 630-637
92. Stark P., and Hardison C.D. A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 46 (1985) 53-58
93. Chang P.P., Ford D.E., Mead L.A., et al. Insomnia in young men and subsequent depression. The Johns Hopkins Precursors Study. Am J Epidemiol 146 (1997) 105-114
94. Breslau N., Roth T., Rosenthal L., et al. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 39 (1996) 411-418
95. Perlis M.L., Giles D.E., Buysse D.J., et al. Self-reported sleep disturbance as a prodromal symptom in recurrent depression. J Affect Disord 42 (1997) 209-212
96. Agargun M.Y., Kara H., and Solmaz M. Sleep disturbances and suicidal behavior in patients with major depression. J Clin Psychiatr 58 (1997) 249-251
97. Hall R.C., and Platt D.E. Suicide risk assessment: a review of risk factors for suicide in 100 patients who made severe suicide attempts. Evaluation of suicide risk in a time of managed care. Psychosomatics 40 (1999) 18-27
98. Chouinard G., Lefko-Singh K., and Teboul E. Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem. Cell Mol Neurobiol 19 (1999) 533-552